Cancer events | Competing events | |||||
---|---|---|---|---|---|---|
Covariate | HR | 95% CI | p-value | HR | 95% CI | p-value |
Age | 0.99 | 0.97–1.01 | 0.6 | 1.03 | 0.1–1.08 | 0.06 |
Sex | ||||||
Male vs Female | 0.59 | 0.28–1.22 | 0.15 | 1.74 | 0.55–5.47 | 0.34 |
Comorbidity | ||||||
0–1 vs 2–6 | 0.86 | 0.48–1.55 | 0.62 | 3.42 | 1.46–7.97 | 0.01 |
ECOG | ||||||
0 vs 1–2 | 1.50 | 1.01–2.21 | 0.04 | 0.94 | 0.42–2.1 | 0.88 |
Stage | ||||||
III vs IV | 1.73 | 1.14–2.63 | 0.01 | 0.63 | 0.25–1.33 | 0.20 |
Technique | ||||||
3DRT vs IMRT | 0.61 | 0.34–1.09 | 0.1 | 0.76 | 0.25–2.30 | 0.63 |
Treatment | ||||||
CRT, RTCTX,ICT | 1.08 | 0.76–1.53 | 0.68 | 1.16 | 0.66–2.06 | 0.60 |
Acute Mucositis | ||||||
0–2 vs 3–5 | 0.80 | 0.51–123 | 0.3 | 1.63 | 0.72–3.68 | 0.24 |
Acute PL toxicity | ||||||
0–2 vs 3–5 | 1.33 | 0.79–2.23 | 0.29 | 1.24 | 0.44–3.48 | 0.69 |
Chronic PL toxicity | ||||||
0–2 vs 3–5 | 0.89 | 0.57–1.38 | 0.60 | 0.78 | 0.36–1.72 | 0.54 |